Richard Ko

1.8k total citations
15 papers, 931 citations indexed

About

Richard Ko is a scholar working on Complementary and alternative medicine, Pharmacology and Pharmacology. According to data from OpenAlex, Richard Ko has authored 15 papers receiving a total of 931 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Complementary and alternative medicine, 5 papers in Pharmacology and 4 papers in Pharmacology. Recurrent topics in Richard Ko's work include Complementary and Alternative Medicine Studies (9 papers), Pharmacology and Obesity Treatment (3 papers) and Nephrotoxicity and Medicinal Plants (3 papers). Richard Ko is often cited by papers focused on Complementary and Alternative Medicine Studies (9 papers), Pharmacology and Obesity Treatment (3 papers) and Nephrotoxicity and Medicinal Plants (3 papers). Richard Ko collaborates with scholars based in United States, China and Iceland. Richard Ko's co-authors include Stephen Bent, Julio A. Chalela, Christine Haller, Alma Au, Brian R. Landzberg, Susan C. Smolinske, Wade Bartlett, Bruce M. Sprague, Lewis S. Nelson and M. Elizabeth Palmer and has published in prestigious journals such as The Lancet, The American Journal of Medicine and Annals of Oncology.

In The Last Decade

Richard Ko

15 papers receiving 841 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Ko United States	10	413	232	232	146	126	15	931
Leala K. Watson United Kingdom	11	525 1.3×	240 1.0×	255 1.1×	138 0.9×	131 1.0×	15	1.1k
Mary L. Chavez United States	12	255 0.6×	257 1.1×	98 0.4×	154 1.1×	148 1.2×	24	933
Barbara Wider United Kingdom	17	584 1.4×	152 0.7×	260 1.1×	168 1.2×	196 1.6×	32	1.2k
Gabriel I. Giancaspro United States	13	219 0.5×	197 0.8×	127 0.5×	167 1.1×	155 1.2×	27	894
Suman Sharma India	23	252 0.6×	157 0.7×	288 1.2×	226 1.5×	163 1.3×	73	1.6k
Debbie Shaw United Kingdom	11	515 1.2×	356 1.5×	299 1.3×	176 1.2×	154 1.2×	17	1.0k
Martha A. Hubbard United States	11	646 1.6×	784 3.4×	272 1.2×	235 1.6×	316 2.5×	16	1.4k
Simona Drăgan Romania	20	284 0.7×	78 0.3×	191 0.8×	314 2.2×	96 0.8×	77	1.6k
Tieraona Low Dog United States	17	443 1.1×	220 0.9×	201 0.9×	151 1.0×	106 0.8×	46	1.3k
Hiroshi Yamada Japan	27	182 0.4×	191 0.8×	61 0.3×	235 1.6×	138 1.1×	81	1.7k

Countries citing papers authored by Richard Ko

Since Specialization

Citations

This map shows the geographic impact of Richard Ko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Ko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Ko more than expected).

Fields of papers citing papers by Richard Ko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Ko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Ko. The network helps show where Richard Ko may publish in the future.

Co-authorship network of co-authors of Richard Ko

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Ko. A scholar is included among the top collaborators of Richard Ko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Ko. Richard Ko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Shukuya, Takehito, Takayuki Asao, Kōji Takayama, et al.. (2024). LBA8 Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma: Marble study. Annals of Oncology. 35. S1631–S1632. 3 indexed citations

Ko, Richard, et al.. (2009). Conventional Weaning Parameters do not Predict Extubation Failure in Neurocritical Care Patients. Neurocritical Care. 10(3). 269–273. 81 indexed citations

Haller, Christine, et al.. (2008). Dietary supplement adverse events: Report of a one-year poison center surveillance project. Journal of Medical Toxicology. 4(2). 84–92. 65 indexed citations

Boylan, Alice M., Richard Ko, Nicholas J. Pastis, et al.. (2008). Common Problems in Critically Ill Obstetric Patients, With an Emphasis on Pharmacotherapy. The American Journal of the Medical Sciences. 335(1). 65–70. 2 indexed citations

Ko, Richard. (2006). Safety of Ethnic & Imported Herbal and Dietary Supplements. Clinical Toxicology. 44(5). 611–616. 23 indexed citations

Dennehy, Cathi, et al.. (2006). Analysis of Ephedra-Free Labeled Dietary Supplements Sold in the San Francisco Bay Area in 2003. Journal of Herbal Pharmacotherapy. 6(2). 1–19. 4 indexed citations

Roman, Mark, Richard Ko, Randall Smith, et al.. (2006). Committee on Dietary Supplements. Journal of AOAC International. 89(6). 1709–1710. 1 indexed citations

Roman, Mark, Richard Ko, Mark L. Anderson, et al.. (2005). Committee on Dietary Supplements. Journal of AOAC International. 88(1). 387–389. 1 indexed citations

Ko, Richard. (2004). A U.S. perspective on the adverse reactions from traditional Chinese medicines.. PubMed. 67(3). 109–16. 67 indexed citations

10.

Bent, Stephen & Richard Ko. (2004). Commonly used herbal medicines in the United States: a review. The American Journal of Medicine. 116(7). 478–485. 327 indexed citations

11.

Palmer, M. Elizabeth, Christine Haller, Patrick E. McKinney, et al.. (2003). Adverse events associated with dietary supplements: an observational study. The Lancet. 361(9352). 101–106. 176 indexed citations

12.

Au, Alma, et al.. (2000). Screening Methods for Drugs and Heavy Metals in Chinese Patent Medicines. Bulletin of Environmental Contamination and Toxicology. 65(1). 112–119. 58 indexed citations

13.

Ko, Richard, et al.. (2000). Screening Methods for Drugs and Heavy Metals in Chinese Patent Medicines. Bulletin of Environmental Contamination and Toxicology. 65(1). 112–119. 40 indexed citations

14.

Ko, Richard. (1999). Causes, Epidemiology, and Clinical Evaluation of Suspected Herbal Poisoning. Journal of Toxicology Clinical Toxicology. 37(6). 697–708. 41 indexed citations

15.

Ko, Richard, et al.. (1996). Lethal ingestion of Chinese herbal tea containing ch'an su.. PubMed. 164(1). 71–5. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact